OCS Stock Forecast & Price Target

Oculis Holding is well positioned by a cash balance of about $278MM at 1Q-end, which is expected to fund operations into 2H29, reducing near-term financing risk while it advances two late-stage assets. Its most compelling driver is the precision-medicine PREDICT-1 program for licaminlimab in DED, enrolling about 160 patients with a genotype-enriched design and topline data expected around the end of 2026, alongside the potential for multiple follow-on DED trials if successful. The other major upside pillar is privosegtor, which has FDA Breakthrough Therapy designation and SPA alignment for PIONEER-1 in optic neuritis, a condition with no approved neuroprotective treatments and a large U.S. market opportunity, supporting meaningful commercial optionality.

Oculis Holding is viewed negatively because its lead OCS-01 program in diabetic macular edema failed both phase 3 DIAMOND-1 and -2 primary endpoints at 52 weeks, forcing discontinuation of that path and leaving the story dependent on less-proven assets. The remaining pipeline still carries heavy development, regulatory, and commercialization uncertainty, with only 45% approval probabilities cited for licaminlimab in dry eye disease and privosegtor in optic neuropathy, while OCS-02 and OCS-05 face explicit U.S. approval and competition risks. Financially, the company is still pre-commercial and may need additional capital as operating expenses rise, with valuation assumptions hinging on $277.6M to $282.3M in cash and potentially 60.4M to 61.8M shares outstanding, increasing dilution risk.